AURA
Aura Biosciences, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $8.30 | $7.47 | -10% |
| Citadel Advisors re-entered | Q3 2024(8Q snapshot) | 7Q | $7.78 | $7.47 | -4% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $7.78 | $7.47 | -4% |
| AQR Capital Management | Q3 2025(8Q snapshot) | 3Q | $7.00 | $7.47 | +7% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $5.25 | $7.47 | +42% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q3 2024 | Q2 2025 | → $5.18 | -33% |
| D.E. Shaw | Q3 2024 | Q1 2025 | → $7.95 | +2% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Aura Biosciences, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from May 19, 2026 — the most recent Form 4 on file — not from today.
- Form 40001580111-26-000009May 19, 2026
- Form 40000950142-26-001346May 11, 2026
- Form 40001193125-26-159579Apr 16, 2026
- Form 40001193125-26-088170Mar 3, 2026
- Form 40001193125-26-088168Mar 3, 2026
- Form 40001193125-26-088162Mar 3, 2026
- Form 40001193125-26-088158Mar 3, 2026
- Form 40001193125-26-088154Mar 3, 2026
- Form 40001193125-26-088150Mar 3, 2026
- Form 40001193125-26-055499Feb 17, 2026
- Form 40001193125-26-055497Feb 17, 2026
- Form 40001193125-26-055496Feb 17, 2026
- Form 40001193125-26-055494Feb 17, 2026
- Form 40001193125-26-055487Feb 17, 2026
- Form 40001193125-26-016939Jan 20, 2026
Fundamentals
XBRL · Aura Biosciences, Inc.Annual figures sourced directly from Aura Biosciences, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Aura Biosciences, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 10-QQuarterly reportMay 11, 2026
- 8-KMaterial eventMay 11, 2026
- 8-KMaterial eventMay 5, 2026
- 8-KMaterial eventMay 4, 2026
- 8-KMaterial eventMay 4, 2026
- DEF 14AProxy statementApr 20, 2026
- 10-KAnnual reportMar 30, 2026
- 8-KMaterial eventMar 30, 2026
- 10-QQuarterly reportNov 13, 2025
- 8-KMaterial eventNov 13, 2025
- 10-QQuarterly reportAug 13, 2025
- 8-KMaterial eventAug 13, 2025
- 8-KMaterial eventJun 18, 2025
- 8-KMaterial eventMay 16, 2025
- 10-QQuarterly reportMay 15, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Citadel Advisors | Q1 2026 | open | $5.25 | $7.47 | +42% |
| Point72 Asset Management | Q1 2026 | open | $5.25 | $7.47 | +42% |
| AQR Capital Management | Q3 2025 | open | $7.00 | $7.47 | +7% |
| Millennium Management | Q3 2025 | open | $7.00 | $7.47 | +7% |
| Citadel Advisors | Q3 2024 | Q4 2025 | $7.78 | $5.53 | -29% |
| Two Sigma Investments | Q3 2024 | Q2 2025 | $7.78 | $5.18 | -33% |
| D.E. Shaw | Q3 2024 | Q1 2025 | $7.78 | $7.95 | +2% |
| Millennium Management | Q3 2024 | Q4 2024 | $7.78 | $9.97 | +28% |
| Renaissance Technologies | Q3 2024 | open | $8.30 | $7.47 | -10% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.